The goal of this educational program is to equip urologists, radiation oncologists, medical oncologists, and other healthcare professionals involved in prostate cancer care with the up-to-date clinical knowledge and tools they need to best treat their patients. The program aims to provide a clinical update on aspects of diagnosis and treatment of localized and advanced disease. The content in this program came from the 24th Southwest Prostate Cancer Symposium, and this is a highlight of the conference.
William K. Oh, MD
Chief, Division of Hematology and Medical Oncology
Deputy Director, Tisch Cancer Institute
Professor of Medicine and Urology
Ezra M. Greenspan, MD, Professor in Clinical Cancer Therapeutics
Icahn School of Medicine at Mount Sinai
New York, New York
Daniel P. Petrylak, MD
Professor of Medicine (Medical Oncology) and Urology
Director, Prostate and GU Medical Oncology
Director, Prostate Cancer Translational Research Group
Yale Cancer Center
New Haven, CT
This activity was developed and is intended primarily for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer.
Over the past three decades, researchers have found a number of treatments, including chemotherapies, anti-androgens, and androgen receptor blockers, that can be used in combination with androgen deprivation therapy to extend survival in patients with this disease.
Many therapeutic options are approved and used for mCRPC. However, fewer options exist for those with non-metastatic (nm) CRPC, also known as M0 prostate cancer. Fortunately, some recent studies on treating nmCRPC have shown promising results.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Medical College of Wisconsin and Carden Jennings Publishing Co., Ltd. The Medical College of Wisconsin is accredited with commendation by the ACCME to provide continuing medical education for physicians.
AMA Credit Designation Statement
The Medical College of Wisconsin designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in these activities.
Hours of Participation for Allied Health Care Professionals: The Medical College of Wisconsin designates this live activity for up to 1.0 hours for continuing education for allied health professionals.
Faculty, Staff, and Planner’s Disclosures
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below:
William K. Oh, MD, has provided the following disclosures:
Consultant for AstraZeneca; Bayer; CPS Companion Diagnostics; Janssen Biotech; Sanofi Genzyme; Sema4; TeneoBio; and Tyme, Inc.
Daniel P. Petrylak, MD, has provided the following disclosures:
Grant/Research Support: Agensys, AstraZeneca, Bayer, Clovis, Dendreon, Eli Lilly, Endocyte, Genentech, Innocrin, Janssen Biotech, MedImmune, Merck, Millennium, Novartis, Pfizer, Progenics, Roche Laboratories, Sanofi Genzyme, Sotio; Consultant: AstraZeneca, Bayer, Bellicum, Dendreon, Exelixis, Ferring, Janssen Biotech, Millennium, Pfizer, Roche Laboratories, Sanofi Genzyme, Bellicum, Tyme, Inc.
The staff of CJP Medical Communications has no relevant financial relationships with commercial interests to disclose.
The staff of the Medical College of Wisconsin has no relevant financial relationships with commercial interests to disclose.
The educational content of this program has been peer-reviewed by The Medical College of Wisconsin.
The material presented at or in any Medical College of Wisconsin or Carden Jennings Publishing Company, Ltd., continuing education activity does not necessarily reflect the views and opinions of Medical College of Wisconsin or Carden Jennings Publishing. Neither Medical College of Wisconsin nor Carden Jennings Publishing, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the U.S. Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME and Support Information
This continuing medical education activity is provided by The Medical College of Wisconsin. Collaborative Partner: Carden Jennings Publishing Co., Ltd.
This activity is supported by an educational grant from Sanofi Genzyme.
1. Gietema JA, Oosting SF, Docetaxel for metastatic prostate cancer: Early is better. Ned Tijdschr Geneeskd. 2016;160:D215.
2. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PAF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomized, double-blind, placebo controlled phase 3 study. The Lancet Oncology. Feb 2015; 16(2): 152-160.
3. James N, et al. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med 2017; 377:338-351.
4. Fizazi K, Tran N, Fein L, et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2017; 377:352-360.
5. Scher HI, Fizazi K, Saad F, et al, for the AFFIRM Investigators. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. N Engl J Med 2012; 367:1187-1197.
6. Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. Phase III study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): The ARCHES trial. J Clin Onc 2019; 37: 687-687.
7. Smith MR, Saad F, Chowdhury S, et al. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. April 2018. N Engl J Med. 2018; 378:1408-1418.
8. Hussain M, Fizazi K, Saad F, et al. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med 2018; 378:2465-2474.
9. Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Nonmetastatic Castration-resistant Prostate Cancer (ARAMIS). Orion Corporation, Orion Pharma and Bayer. July 2014 - [Cited 2018 Oct 24]. Available from: https://clinicaltrials.gov/ct2/show/NCT02200614. NLM Identifier: NCT02200614.
10. James ND et al. ASCO 2015. Abstract 5001.
The following learning objectives were developed to address the identified learning gaps.
Upon completion of the conference, participants will be able to:
Evaluate the role of hormone therapy and target agents combined with chemotherapy in metastatic disease
Discuss the treatment of advanced disease, specifically in the non-metastatic CRPC disease state
Assess the treatment of oligometastatic prostate cancer with recent advancements
By completing/passing this course, you will attain the certificate MCW CME Certificate
Your cart is empty